In this video, Motley Fool health-care analyst David Williamson takes a closer look at what has propelled Aegerion Pharmaceuticals (NASDAQ: AEGR) to new heights and what it means for its potential competitor Isis Pharmaceuticals (IONS -1.55%). He also discusses Merck's (MRK 1.77%) latest stumble, a failed study that may get an approved drug pulled from the market.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
The stock is hitting new 52-week highs post FDA approval.
David Williamson has no positions in the stocks mentioned above. Follow him on Twitter @MotleyDavid.
The Motley Fool has no positions in the stocks mentioned above. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Merck
MRK
$81.74
(1.77%)
$1.42
Sanofi
SNY
$50.86
(2.33%)
$1.16
Ionis Pharmaceuticals
IONS
$35.63
(-1.55%)
$0.56
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Why Novo Nordisk Stock Pumped Higher on Thursday
Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?
Create a Portfolio of Passive Income: 3 High-Yielding Dividend Stocks That Pay More Than 5%
Should You Buy UnitedHealth Stock Instead of Novo Nordisk Stock?
Opinion: It's Time to Buy UnitedHealth Group Stock After a 50% Plunge
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.